Corient Private Wealth’s NovoCure NVCR Stock Holding History

Corient Private Wealth’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$934K	Sell	61,650 -154,863	-72%	-$2.34M	﹤0.01%	1860
2026 Q1	$2.33M	Buy	216,513 +169,561	+361%	+$2.12M	﹤0.01%	1180
2025 Q4	$608K	Buy	46,952 +11,925	+34%	+$153K	﹤0.01%	1766
2025 Q3	$453K	Buy	35,027 +16,491	+89%	+$220K	﹤0.01%	1852
2025 Q2	$330K	Buy	18,536 +6,592	+55%	+$115K	﹤0.01%	1934
2025 Q1	$213K	Buy	+11,944	New	+$271K	﹤0.01%	2038
2023 Q2	–	Sell	-4,932	Closed	-$297K	–	2132
2023 Q1	$297K	Buy	4,932 +1,912	+63%	+$153K	﹤0.01%	1612
2022 Q4	$222K	Buy	+3,020	New	+$227K	﹤0.01%	1454

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Corient Private Wealth's NVCR Position: Q2 2026 in Review

Corient Private Wealth reduced its NovoCure (NVCR) stake by 72% in Q2 2026, selling an estimated $2.34M and leaving 61,650 shares worth $934K. The position accounts for ﹤0.01% of the portfolio, ranked #1860.

Corient Private Wealth first reported a position in NVCR in Q4 2022 and has held it in 8 quarters since. The position peaked at $2.33M in Q1 2026. 216 funds tracked by Wall St. Rank hold NVCR as of Q2 2026.

Corient Private Wealth held 61,650 shares of NovoCure worth $934K as of Q2 2026.
Corient Private Wealth sold 154,863 NovoCure shares in Q2 2026, an estimated $2.34M.
NovoCure made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1860 holding.
Corient Private Wealth first reported a position in NovoCure in Q4 2022 and has held it in 8 quarters since.
Corient Private Wealth's NovoCure position peaked at $2.33M in Q1 2026.
216 funds tracked by Wall St. Rank held NovoCure as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.